Journal Article

Tolerability of Postexposure Prophylaxis with Zidovudine, Lamivudine, and Nelfinavir for Human Immunodeficiency Virus Infection

Christian Rabaud, Sibylle Bevilacqua, Isabelle Beguinot, Véronique Dorvaux, Hélène Schuhmacher, Thierry May and Philippe Canton

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 32, issue 10, pages 1494-1495
Published in print May 2001 | ISSN: 1058-4838
Published online May 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/320166
Tolerability of Postexposure Prophylaxis with Zidovudine, Lamivudine, and Nelfinavir for Human Immunodeficiency Virus Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Tolerability of the combination of zidovudine, lamivudine, and nelfinavir used as postexposure prophylaxis (PEP) for HIV infection was prospectively evaluated among 185 patients at 11 hospitals in eastern France. After exclusion of the 106 persons who discontinued PEP either because the source patient subsequently tested HIV seronegative or because the injury was reassessed as resulting in a low risk for transmission of HIV, 67 (85%) of the patients who received such PEP experienced adverse effects, which led to withdrawal of nelfinavir in 28 (35%) of these patients.

Journal Article.  1043 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.